Eurobench.com

PBos 13 september 2023 08:55

0

www.lse.co.uk/rns/NCYT/notice-of-resu...

voda 13 september 2023 15:36

1

Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)
Notice of Half Year 2023 Results and Investor Presentation

Paris, France and Eastleigh, UK – 13 September 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces that it will report its unaudited financial results for the six
months ended 30 June 2023 on Thursday, 28 September 2023.

Investor webinar

An investor webinar presentation by James McCarthy, Acting Chief Executive Officer, Steve Gibson, Group Finance
Director and Lyn Rees, Executive Director and former CEO of Yourgene, covering the H1 2023 results will take place
at 12.30pm BST on Thursday, 28 September 2023.

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A
session, held on the Investor Meet Company platform. Questions can be submitted pre-event via your Investor
Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation.
Automated French subtitling will be available throughout the presentation.
Investors can sign up for the webinar via:

www.investormeetcompany.com/novacyt-s...
Investors who already follow NOVACYT S.A. on the Investor Meet Company platform will automatically be invited.

novacyt.com/notice-of-half-year-2023-...

DeZwarteRidder 13 september 2023 15:55

1

28 September 2023 wordt natuurlijk een grote feestdag.....!!!

PBos 14 september 2023 08:22

1

www.lse.co.uk/rns/NCYT/agm-voting-dln...

voda 14 september 2023 08:26

1

Novacyt S.A.

(“Novacyt”, the “Company” or the “Group”)

AGM voting

Paris, France, and Eastleigh UK – 14 September 2023 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces that shareholders are now able to vote for the Company’s
rescheduled Annual General Meeting (“AGM”), which will be held at 1pm BST/2pm CEST on 5 October 2023 as an
open virtual meeting.

The Company’s Annual General Meeting (“AGM”) will be held exclusively as an open online meeting at 1pm
BST/2pm CEST on Thursday, 5 October 2023. As this is a rescheduled meeting, all previous votes are now void and
all shareholders must resubmit their votes.

As usual, and in accordance with French corporate law, the AGM comprises both ordinary and extraordinary
resolutions. All materials can be found at www.novacyt.com/investors.
Shareholders are strongly encouraged to submit their votes in advance, in accordance with the instructions in the
Notice of the AGM.

Under French law, for the AGM and EGM meetings to be quorate at the first attempt, shareholders representing at
least 20% of the share capital and voting rights, on ordinary resolutions, and 25% of the share capital and voting
rights, on extraordinary resolutions, must be present, represented or have voted in advance under the conditions
set out below.

Shareholders can vote in advance of the AGM by:
• Downloading a copy of the proxy voting form from the website www.novacyt.com/investors, completing it
and returning it together with evidence of their shareholding which must be in the form of a share
certificate (attestation), either by post to the following address: 6 avenue de Provence 75452 Paris Cedex
09, or via email to the following address: serviceproxy@cic.fr, or investor.relations@novacyt.com, no later
than 2 October 2023 inclusive.
• Voting on-line using the Votaccess portal www.actionnaire.cic-marketsolutions.eu if securities held
on Euronext Growth are registered with any of the following banks: CIC, Natixis, Société Générale, Caceis,
Crédit Agricole, BP2S, BNP Retail, Bourse Direct, ODDO, Rothschild Martin Maurel, Procapital, Citibank,
Deutsche Bank, Bank of New York or JP Morgan. The Votaccess portal will be open from 15 September 2023
to 4 October 2023 2pm BST/3pm CEST.
• Voting on-line via a broker, nominee, bank or authorised intermediary. Many intermediaries in the UK such
as Hargreaves Lansdown are now using the Broadridge ProxyVote on-line voting portal.

Shareholders can register for the AGM and access the online meeting by visiting
novacytagm23.eventcaster.co.uk. Registration must be accompanied by formal evidence of shareholding.
As this is a rescheduled meeting, all previous registrations are now void and all shareholders must re-register.
Following registration approval, shareholders will be able to virtually attend the AGM and vote online during the
meeting if they wish, providing formal evidence of holding has been provided prior to the meeting.

Shareholders who have voted (through a proxy, via their broker, nominee, bank, authorised intermediary,
Votaccess portal or Broadridge ProxyVote) will be allowed to attend the AGM online but will not be able to vote
twice.

Following the meeting, a recording of the AGM will be available on the Company’s website at
www.novacyt.com/investors.

novacyt.com/agm-voting-4/

cruiser2010 14 september 2023 08:42

0

Nipt vergoeding is rond door verzekeraars in de US

Louis7 14 september 2023 12:05

0

www.linkedin.com/posts/novacyt.co.uk_...

mvliex 1 15 september 2023 11:09

0

Mooi zaagpatroon in de koers van afgelopen maand. Jammer dat je nooit zeker weet of dat zich voortzet.
;-)

voda 15 september 2023 17:13

0

Kabinet rekent op 4 miljoen herhaalvaccinaties tegen corona: 300.000 prikken per week in GGD-hallen

Komend najaar komt er weer een grote coronavaccinatiecampagne. Vanaf oktober tot het einde van het jaar kunnen alle 60-plussers, de griepprikgroep, zwangeren, mensen met afweerstoornissen en zorgmedewerkers een herhaalprik krijgen. Dat gebeurt voornamelijk in GGD-locaties.

Niels Klaassen 13-09-23, 13:26 Laatste update: 13-09-23, 15:25
Dat meldt minister van Volksgezondheid Ernst Kuipers (D66) in een brief aan de Tweede Kamer. Het coronavirus veroorzaakt allang geen crisissituatie meer, maar mensen in risicogroepen en ouderen kunnen nog altijd flink ziek worden door een besmetting. Zij krijgen vanaf oktober de gelegenheid een herhaalprik te halen tegen het virus, de vaccinaties zijn aangepast op omikronvariant XBB 1.5.

Voor meer, zie link:

www.ad.nl/politiek/kabinet-rekent-op-...

voda 15 september 2023 17:48

1

Slotkoers 31 dec. 2022 1,2295

Slotkoers 06 jan. 2023 1,0355 -0,194 = -15.78% Enorm volatiele week.
Slotkoers 13 jan. 2023 0,943 -0,0925 = -8.93%
Slotkoers 20 jan. 2023 0,8866 -0,0564 = -5.98%
Slotkoers 27 jan. 2023 0,853 -0,0336 = -3.79%
Slotkoers 03 feb. 2023 0,7768 -0,0762 = -8.93%
Slotkoers 10 feb. 2023 0,7534 -0,0234 = -3.01%
Slotkoers 17 feb. 2023 0,72 -0,0334 = -4.43%
Slotkoers 24 feb. 2023 0,7362 +0,0162 = +2.25% De eerste week met een PLUSJE
Slotkoers 03 mrt. 2023 0,6938 -0,0424 = -5.76%
Slotkoers 10 mrt. 2023 0,66 -0,0338 = -4.87%
Slotkoers 17 mrt. 2023 0,6206 -0,0394 = -5.97%
Slotkoers 24 mrt. 2023 0,612 -0,0086 = -1.39%
Slotkoers 31 mrt. 2023 0,64 +0,028 = +4.58%
Slotkoers 06 apr. 2023 0,625 -0,015 = -2.34%
Slotkoers 14 apr. 2023 0,6335 +0,085 = +1.36%
Slotkoers 21 apr. 2023 0,591 -0,0425 = -6.71%
Slotkoers 28 apr. 2023 0,5625 -0,0285 = -4.82% PB Finale eindcijfers 2022
Slotkoers 05 mei 2023 0,5175 -0,045 = -8.00%
Slotkoers 12 mei 2023 0,499 -0,0185 = -3.57%
Slotkoers 19 mei 2023 0,479 -0,02 = -4.01%
Slotkoers 26 mei 2023 0,4662 -0,0128 = -2.67%
Slotkoers 02 jun. 2023 0,481 +0,0148 = +3.17% Eindelijk een ommekeer?
Slotkoers 09 jun. 2023 0,496 +0,015 = +3.12%
Slotkoers 16 jun. 2023 0,4612 -0,0348 = -7.02%
Slotkoers 23 jun. 2023 0,4406 -0,0206 = -4.47%
Slotkoers 30 jun. 2023 0,4238 -0,0168 = -3.81%
Slotkoers 07 jul. 2023 0,4788 +0,055 = +12.98% PB Overname Yourgene (Top was 0,59 ruim 40%)
Slotkoers 14 jul. 2023 0,515 +0,0362 = +7.56%
Slotkoers 21 jul. 2023 0,54 +0,025 = +4.85%
Slotkoers 28 jul. 2023 0,716 +0,176 = +32.59% PB Trading update 1 st halfyear.
Slotkoers 04 aug. 2023 0,725 +0,009 = +1.26%
Slotkoers 11 aug. 2023 0,888 +0,163 = +22.48%
Slotkoers 18 aug. 2023 0,931 +0,043 = +4.84% PB Overname Yourgene akkoord.
Slotkoers 25 aug. 2023 0,866 -0,065 = -6.98%
Slotkoers 01 sep. 2023 0,86 -0,006 = -0.69%
Slotkoers 08 sep. 2023 0,931 +0,071 = +8.26% PB Yourgene
Slotkoers 15 sep. 2023 0,8325 - 0,0985 = -10.58%

Jaarrendement t.o.v. van 31 december 2022 -0,397 = -32.29%

Maandrendementen: (t.o.v. slot vorige maand)

Slotkoers 31 jan. 2023 0,8084 -0,4211 = -34.25%
Slotkoers 28 feb. 2023 0,709 -0,0994 = -12.30%
Slotkoers 31 mrt. 2023 0,64 -0,069 = -9.73%
Slotkoers 28 apr. 2023 0,5625 -0,0775 = -12.11%
Slotkoers 31 mei 2023 0,466 -0,0965 = -17.16%
Slotkoers 30 jun. 2023 0,4238 -0,0422 = -9.06%
Slotkoers 31 jul. 2023 0,7295 +0.3057 = +72.13!!%
Slotkoers 31 aug. 2023 0,885 +0,1555 = +21.32%
Slotkoers 15 sep. 2023 0,8325 -0,0525 = -5.93%

voda 18 september 2023 15:33

1

Het is jammer dat de koers nu weer zover terugloopt. Hebben wij al vaker in het verleden gezien. Had gehoopt dat het nu stabieler zou zijn.

0,7900
-0,0425
/
-5,11%
15:28:35

Nait Soesen 20 september 2023 22:12

1

From next week, the Biden Administration will make every US household eligible to receive four free COVID tests.

Louis7 22 september 2023 00:18

1

quote:
Nait Soesen schreef op 20 september 2023 22:12:
From next week, the Biden Administration will make every US household eligible to receive four free COVID tests.

Hierbij de link:

edition.cnn.com/2023/09/20/health/fre...

voda 22 september 2023 17:53

1

Slotkoers 31 dec. 2022 1,2295

Slotkoers 06 jan. 2023 1,0355 -0,194 = -15.78% Enorm volatiele week.
Slotkoers 13 jan. 2023 0,943 -0,0925 = -8.93%
Slotkoers 20 jan. 2023 0,8866 -0,0564 = -5.98%
Slotkoers 27 jan. 2023 0,853 -0,0336 = -3.79%
Slotkoers 03 feb. 2023 0,7768 -0,0762 = -8.93%
Slotkoers 10 feb. 2023 0,7534 -0,0234 = -3.01%
Slotkoers 17 feb. 2023 0,72 -0,0334 = -4.43%
Slotkoers 24 feb. 2023 0,7362 +0,0162 = +2.25% De eerste week met een PLUSJE
Slotkoers 03 mrt. 2023 0,6938 -0,0424 = -5.76%
Slotkoers 10 mrt. 2023 0,66 -0,0338 = -4.87%
Slotkoers 17 mrt. 2023 0,6206 -0,0394 = -5.97%
Slotkoers 24 mrt. 2023 0,612 -0,0086 = -1.39%
Slotkoers 31 mrt. 2023 0,64 +0,028 = +4.58%
Slotkoers 06 apr. 2023 0,625 -0,015 = -2.34%
Slotkoers 14 apr. 2023 0,6335 +0,085 = +1.36%
Slotkoers 21 apr. 2023 0,591 -0,0425 = -6.71%
Slotkoers 28 apr. 2023 0,5625 -0,0285 = -4.82% PB Finale eindcijfers 2022
Slotkoers 05 mei 2023 0,5175 -0,045 = -8.00%
Slotkoers 12 mei 2023 0,499 -0,0185 = -3.57%
Slotkoers 19 mei 2023 0,479 -0,02 = -4.01%
Slotkoers 26 mei 2023 0,4662 -0,0128 = -2.67%
Slotkoers 02 jun. 2023 0,481 +0,0148 = +3.17% Eindelijk een ommekeer?
Slotkoers 09 jun. 2023 0,496 +0,015 = +3.12%
Slotkoers 16 jun. 2023 0,4612 -0,0348 = -7.02%
Slotkoers 23 jun. 2023 0,4406 -0,0206 = -4.47%
Slotkoers 30 jun. 2023 0,4238 -0,0168 = -3.81%
Slotkoers 07 jul. 2023 0,4788 +0,055 = +12.98% PB Overname Yourgene (Top was 0,59 ruim 40%)
Slotkoers 14 jul. 2023 0,515 +0,0362 = +7.56%
Slotkoers 21 jul. 2023 0,54 +0,025 = +4.85%
Slotkoers 28 jul. 2023 0,716 +0,176 = +32.59% PB Trading update 1 st halfyear.
Slotkoers 04 aug. 2023 0,725 +0,009 = +1.26%
Slotkoers 11 aug. 2023 0,888 +0,163 = +22.48%
Slotkoers 18 aug. 2023 0,931 +0,043 = +4.84% PB Overname Yourgene akkoord.
Slotkoers 25 aug. 2023 0,866 -0,065 = -6.98%
Slotkoers 01 sep. 2023 0,86 -0,006 = -0.69%
Slotkoers 08 sep. 2023 0,931 +0,071 = +8.26% PB Yourgene
Slotkoers 15 sep. 2023 0,8325 - 0,0985 = -10.58%
Slotkoers 22 sep. 2023 0,78 - 0,0525 = -6.31%

Jaarrendement t.o.v. van 31 december 2022 -0,4495 = -36.56%

Maandrendementen: (t.o.v. slot vorige maand)

Slotkoers 31 jan. 2023 0,8084 -0,4211 = -34.25%
Slotkoers 28 feb. 2023 0,709 -0,0994 = -12.30%
Slotkoers 31 mrt. 2023 0,64 -0,069 = -9.73%
Slotkoers 28 apr. 2023 0,5625 -0,0775 = -12.11%
Slotkoers 31 mei 2023 0,466 -0,0965 = -17.16%
Slotkoers 30 jun. 2023 0,4238 -0,0422 = -9.06%
Slotkoers 31 jul. 2023 0,7295 +0.3057 = +72.13!!%
Slotkoers 31 aug. 2023 0,885 +0,1555 = +21.32%
Slotkoers 22 sep. 2023 0,78 -0,105 = -11.86%

voda 28 september 2023 08:08

0

Please find the attached RNS issued this morning.

An investor webinar presentation by James McCarthy, Acting Chief Executive Officer, Steve Gibson, Group Finance Director and Lyn Rees, Executive Director and former CEO of Yourgene, covering the H1 2023 results will take place at 12.30pm BST today.

The webinar is open to all existing and potential investors, and will consist of a presentation followed by a Q&A session, held on the Investor Meet Company platform. Automated French subtitling will be available throughout the presentation.

Investors can sign up for the webinar via:

www.investormeetcompany.com/novacyt-s...

Kind regards,

Mandy Cowling

Corporate and Investor Relations Manager

mandy.cowling@novacyt.com

Novacyt Group

www.novacyt.com

LinkedIn

Mobile: +44 (0) 7785 541 259

York House, School Lane, Chandlers Ford, Eastleigh, SO53 4DG?

voda 28 september 2023 08:12

0

The interim results (in pdf format)

novacyt.com/wp-content/uploads/2023/0...

voda 28 september 2023 08:16

0

Ach ja, wordt dit ooit nog opgelost?

Trade and other receivables has fallen by £0.4m to £33.3m at 30 June 2023 in line with a decline in sales. The trade receivables balance includes a £24.0m unpaid DHSC invoice raised in December 2020, in respect of products delivered during 2020 that remains unpaid at the date of publishing the accounts. Recovery of the invoice is dependent on the outcome of the contract dispute. Also included in trade and other receivables is a £8.2m VAT receivable balance (December 2022: £8.3m), that mainly relates to UK VAT paid on sales invoices in dispute with the DHSC. As these sales have not been recognised in accordance with IFRS 15, the revenue, trade receivable and VAT element of the transactions have been reversed, resulting in a VAT debtor balance.

DeZwarteRidder 28 september 2023 08:19

0

Novacyt S.A.
(“Novacyt”, the “Company” or the “Group”)
2023 Interim Results
Company positioned for long-term sustainable growth following the acquisition of Yourgene Health
Paris, France and Eastleigh, UK – 28 September 2023 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an
international specialist in clinical diagnostics, announces its unaudited interim results for the six months ended 30
June 2023.
Operational highlights (including post-period end)
• Completed the strategic acquisition of Yourgene Health plc (“Yourgene”), significantly enhancing Novacyt’s
global diagnostics business, adding scale and diversification to accelerate long-term growth.
• Successfully developed nine multiplex RUO (research use only) assays in key infectious disease areas.
• IVD certification process: initiated verification and validation activities for two of the Company’s developed
multiplex products, with the aim of certifying them as in vitro diagnostics (IVD) under the UKCA mark,
expected to complete during Q4 2023.
• Instrument sales recovery: Following the market saturation during the COVID-19 pandemic, the Group’s
instrument sales are returning to normal levels with Q2 2023 sales up by 66% vs Q1 2023.
• Recently launched Co-prep™ extraction system for research use and CE marked both q16 and q32
instruments.
• On track to complete IVDR clinical trial for winter respiratory panel, genesig™ Real-time PCR SARS-CoV-2
Winterplex, in early 2024.
• Exclusive development agreement with Eluceda Ltd to develop novel biosensor technology in the fields of
human and animal in vitro diagnostics, life science research and animal speciation.

Financial highlights
• Group revenue for H1 2023 of £3.3m of which £0.5m relates to COVID-19 (H1 2022: £16.5m of which
£13.0m was related to COVID-19).
o Revenue for the non-COVID-19 portfolio totalled £2.8m representing 85% of total revenue (H1
2022: £3.5m). As previously signalled, H1 2022 is a high comparator particularly in instrumentation,
where sales were linked to COVID-19.
o Non-COVID-19 revenue continues to build with Q2 2023 showing 3% growth over Q1 2023 and 10%
growth vs Q4 2022.
• Group gross margin increased to 50% (£1.7m) in H1 2023 (H1 2022: 24% (£4.0m)), due to lower stock write
offs, but is still impacted by further stock provisions as a result of lower than anticipated COVID-19 sales.
• Group operating costs fell by £4.1m to £7.0m in H1 2023 compared with £11.1m in H1 2022.
• Group EBITDA loss before exceptionals reduced to £5.4m in H1 2023 (H1 2022: £7.1m loss).
• Loss after tax reduced to £8.3m in H1 2023 (H1 2022: £8.7m).
• Cash position at 30 June 2023 was £81.7m (FY 2022: £87.0m) and the Company remains debt free.
• Acquired the entire share capital of Yourgene on 8 September 2023 for £16.7m, settled in cash.

PBos 28 september 2023 09:18

0

Omzet van niks, maar dat wisten we al. Het is te hopen dat met Yourgene erbij, ze eindelijk is wat gaan verkopen.

trab33 28 september 2023 15:24

0

quote:
PBos schreef op 28 september 2023 09:18:
Omzet van niks, maar dat wisten we al. Het is te hopen dat met Yourgene erbij, ze eindelijk is wat gaan verkopen.

niks + niks = noppes ,,,,kosten zullen enkel verder blijven oplopen

Vertraagd	8 mei 2024 16:46
Koers	0,762
Verschil	-0,008 (-1,04%)
Hoog	0,770
Laag	0,750
Volume	74.249
Volume gemiddeld	190.092
Volume gisteren	96.514

Novacyt « Terug naar discussie overzicht

Novacyt de volgende biotech raket!

Meedoen aan de discussie?

Direct naar Forum

Detail

Novacyt nieuws